LXR activation is known to inhibit proliferation of breast cancer cells53 and FXR activation in breast cancer cells results in cytotoxicity.54 Activated FXR can also counteract the tumour promoting ability of cancer-associated fibroblasts within the breast cancer microenvironment.55 Therefore, one might hypothesise that the removal of LXR and FXR pathway components in control cell EVs suggests that normal proliferation occurs. The gene discussed is NR1H4; the disease is breast cancer.